SCHEMBL5362415

SCHEMBL5362415

COC=Cc1cc(OC(C)C)c(OC)cc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 1/20 0.49
HPGD P15428 2/20 0.42
KDM1A O60341 1/20 0.42
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HMGCR P04035 1/20 0.36
CYP3A4 P08684 1/20 0.36
NFE2L2 Q16236 1/20 0.36
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ACHE P22303 1/20 0.35
PDE4B Q07343 1/20 0.34
HTR2A P28223 3/20 0.33
TAAR1 Q96RJ0 2/20 0.33
LCK P06239 1/20 0.33
FYN P06241 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5362409 1.00 PRKDC (0.49) PRKDCHPGDKDM1AMAPTNPSR1
SCHEMBL660822 0.81 PRKDC (0.77) PRKDCHPGDKDM1AMAPTNPSR1
SCHEMBL28786078 0.81 PRKDC (0.77) PRKDCHPGDKDM1AMAPTNPSR1
SCHEMBL14581263 0.77 PRKDC (0.46) PRKDCHPGDKDM1AMAPTNPSR1
SCHEMBL31412995 0.72 MAPT (0.56) HPGDMAPTMEN1KMT2AALDH1A1
SCHEMBL5028964 0.71 MAPT (0.44) PRKDCMAPTNPSR1L3MBTL1ACHE
SCHEMBL5028969 0.71 MAPT (0.44) PRKDCMAPTNPSR1L3MBTL1ACHE
SCHEMBL14581179 0.71 MAPT (0.44) PRKDCMAPTNPSR1HMGCRL3MBTL1
SCHEMBL23783272 0.71 PRKDC (0.61) PRKDCHPGDMAPTNPSR1ALDH1A1
SCHEMBL28844605 0.71 MAPT (0.43) MAPTNPSR1L3MBTL1HTR2ATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070027138-A1 Derivatives and analogs of galanthamine SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT 2007-02-01 US disclosed
US-20070027138-A1 Derivatives and analogs of galanthamine SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT 2007-02-01 US disclosed
US-7166588-B2 Derivatives and analogs of galanthamine SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) 2007-01-23 US disclosed
US-7166588-B2 Derivatives and analogs of galanthamine SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) 2007-01-23 US disclosed
EP-1181294-B1 NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN SANOCHEMIA PHARMAZEUTIKA AG (AT) 2004-03-31 EP disclosed
US-20030199493-A1 Novel derivatives and analogues of galanthamin SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) 2003-10-23 US disclosed
EP-1181294-A1 NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN Sanochemia Pharmazeutika Aktiengesellschaft (AT) 2002-02-27 EP disclosed
WO-2001074820-A1 NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027138-A1 Derivatives and analogs of galanthamine GALR2, GALR1, GALR3 PRKDC 4793/4885HPGD 1021/4885KDM1A 2663/4885
US-20030199493-A1 Novel derivatives and analogues of galanthamin GALR1, GALNT1, GALK1 PRKDC 3744/4885HPGD 1506/4885KDM1A 3793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.